Telmisartan 40 Teva, Telmisartan 80 Teva 40 mg, 80mg Tablets
PDF Leaflet Revision Date: 21 January 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate hypertension and reduction of cardiovascular risk in high-risk patients.
Dosage (summary)
40 mg once daily; may increase to 80 mg if needed.
Onset of Action / Duration
Onset: 3 hours, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity
- Angioedema history
- Bilateral renal artery stenosis
- Severe renal impairment
- Pregnancy
- Severe hepatic impairment
Common side effects
- Cough
- Hyperkalaemia
- Hypotension
- Dizziness
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of angioedema
Serious warnings
- Risk of hypotension in volume-depleted patients
- Dual blockade of RAAS contraindicated
Important Disclaimer
The Telmisartan 40 Teva, Telmisartan 80 Teva 40 mg, 80mg Tablets professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
